Market Cap ₹23921 Cr.
Stock P/E 43.4
P/B 6.4
Current Price ₹5228.9
Book Value ₹ 819.9
Face Value 10
52W High ₹6452.9
Dividend Yield 0.67%
52W Low ₹ 4015.1
Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, anti-infectives, cardiovascular, dermatology, Trulimax, Vibazime DT, Ovral G, Ovral L, Premarin pills, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The Company has its personal production facility at Thane and Goa. The Company has numerous impartial settlement/third party manufacturers based throughout the country.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
#(Fig in Cr.) | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 593 | 637 | 622 | 573 | 531 | 575 | 540 | 547 | 563 | 589 |
Other Income | 18 | 24 | 27 | 31 | 33 | 36 | 36 | 75 | 42 | 43 |
Total Income | 611 | 662 | 649 | 604 | 565 | 611 | 576 | 622 | 605 | 632 |
Total Expenditure | 401 | 406 | 418 | 391 | 421 | 393 | 387 | 357 | 385 | 399 |
Operating Profit | 210 | 256 | 231 | 213 | 144 | 219 | 188 | 265 | 219 | 232 |
Interest | 4 | 3 | 4 | 3 | 3 | 3 | 3 | 7 | 2 | 2 |
Depreciation | 27 | 26 | 26 | 26 | 16 | 15 | 18 | 14 | 15 | 15 |
Exceptional Income / Expenses | -136 | 189 | 0 | -20 | 0 | 0 | 8 | 0 | 0 | 0 |
Profit Before Tax | 43 | 415 | 201 | 165 | 126 | 201 | 176 | 244 | 203 | 215 |
Provision for Tax | 11 | 104 | 50 | 35 | 32 | 52 | 46 | 65 | 52 | 57 |
Profit After Tax | 33 | 311 | 151 | 130 | 94 | 149 | 130 | 179 | 151 | 158 |
Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 33 | 311 | 151 | 130 | 94 | 149 | 130 | 179 | 151 | 158 |
Adjusted Earnings Per Share | 7.1 | 68 | 32.9 | 28.3 | 20.4 | 32.6 | 28.4 | 39.1 | 32.9 | 34.6 |
#(Fig in Cr.) | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 1112 | 1853 | 2012 | 1966 | 1969 | 2082 | 2152 | 2239 | 2611 | 2425 | 2193 | 2239 |
Other Income | 109 | 72 | 87 | 101 | 114 | 167 | 184 | 81 | 63 | 101 | 181 | 196 |
Total Income | 1221 | 1925 | 2099 | 2067 | 2083 | 2249 | 2336 | 2320 | 2674 | 2526 | 2374 | 2435 |
Total Expenditure | 873 | 1474 | 1579 | 1616 | 1468 | 1516 | 1579 | 1526 | 1775 | 1616 | 1558 | 1528 |
Operating Profit | 349 | 451 | 520 | 451 | 615 | 733 | 757 | 794 | 899 | 910 | 816 | 904 |
Interest | 1 | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 14 |
Depreciation | 8 | 131 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 62 |
Exceptional Income / Expenses | 0 | -80 | 10 | 130 | 0 | 0 | 0 | 0 | 0 | 33 | 8 | 8 |
Profit Before Tax | 340 | 238 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 838 |
Provision for Tax | 119 | 138 | 165 | 180 | 188 | 231 | 133 | 171 | 160 | 200 | 195 | 220 |
Profit After Tax | 221 | 100 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 618 |
Adjustments | 0 | -31 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit After Adjustments | 221 | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 618 |
Adjusted Earnings Per Share | 74 | 21.9 | 66.7 | 73.6 | 78.7 | 93.8 | 111.3 | 108.8 | 133.9 | 136.4 | 120.5 | 135 |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Sales CAGR | -10% | -1% | 1% | 7% |
Operating Profit CAGR | -10% | 1% | 2% | 9% |
PAT CAGR | -12% | 3% | 5% | 10% |
# | 1 Year | 3 Year | 5 Year | 10 Year |
---|---|---|---|---|
Share Price CAGR | 28% | 2% | 4% | 10% |
ROE Average | 16% | 20% | 19% | 16% |
ROCE Average | 22% | 27% | 25% | 24% |
#(Fig in Cr.) | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
Shareholder's Funds | 658 | 1973 | 2163 | 2419 | 2683 | 3011 | 3395 | 2393 | 2864 | 3207 | 3596 |
Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Borrowings | 0 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -19 | -37 | 64 | 62 | 52 | 37 | 136 | 85 | 136 | 38 | 33 |
Total Current Liabilities | 303 | 609 | 658 | 780 | 954 | 892 | 873 | 774 | 853 | 657 | 547 |
Total Liabilities | 942 | 2547 | 2888 | 3261 | 3690 | 3940 | 4405 | 3252 | 3854 | 3903 | 4175 |
Fixed Assets | 20 | 944 | 925 | 867 | 917 | 854 | 942 | 865 | 841 | 749 | 713 |
Other Non-Current Assets | 237 | 350 | 331 | 343 | 357 | 371 | 415 | 479 | 616 | 629 | 693 |
Total Current Assets | 686 | 1252 | 1614 | 2033 | 2403 | 2702 | 3013 | 1873 | 2361 | 2493 | 2738 |
Total Assets | 942 | 2547 | 2888 | 3261 | 3690 | 3940 | 4405 | 3252 | 3854 | 3903 | 4175 |
#(Fig in Cr.) | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
Opening Cash & Cash Equivalents | 1433 | 308 | 488 | 71 | 68 | 51 | 74 | 1764 | 151 | 63 | 37 |
Cash Flow from Operating Activities | 132 | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 |
Cash Flow from Investing Activities | 103 | -89 | -701 | -250 | -238 | 35 | 1530 | -469 | -575 | -36 | 54 |
Cash Flow from Financing Activities | -1360 | -1 | -62 | -83 | -110 | -110 | -164 | -1571 | -181 | -346 | -235 |
Net Cash Inflow / Outflow | -1125 | 23 | -417 | -3 | -17 | 23 | 1690 | -1613 | -88 | -26 | 75 |
Closing Cash & Cash Equivalent | 308 | 488 | 71 | 68 | 51 | 74 | 1764 | 151 | 63 | 37 | 112 |
# | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
Earnings Per Share (Rs) | 74.01 | 21.93 | 66.67 | 73.61 | 78.7 | 93.78 | 111.29 | 108.77 | 133.89 | 136.38 | 120.51 |
CEPS(Rs) | 76.68 | 50.59 | 79.33 | 87.37 | 93.18 | 109.39 | 133.85 | 132.68 | 159.03 | 159.44 | 134.12 |
DPS(Rs) | 360 | 12.5 | 15 | 20 | 20 | 22.5 | 330 | 35 | 30 | 70 | 35 |
Book NAV/Share(Rs) | 220.64 | 431.28 | 472.92 | 528.72 | 586.49 | 658.22 | 742.18 | 523.07 | 626.1 | 701.05 | 785.91 |
Core EBITDA Margin(%) | 20.54 | 19.69 | 20.67 | 17.15 | 25.28 | 27.17 | 26.62 | 31.82 | 30.79 | 31.6 | 27.43 |
EBIT Margin(%) | 29.24 | 12.43 | 22.53 | 25.41 | 27.71 | 31.79 | 30.37 | 30.56 | 28.86 | 32.71 | 32.88 |
Pre Tax Margin(%) | 29.15 | 12.36 | 22.47 | 25.31 | 27.67 | 31.7 | 29.86 | 29.87 | 28.46 | 32.18 | 32.21 |
PAT Margin (%) | 18.96 | 5.21 | 14.57 | 16.49 | 18.18 | 20.61 | 23.66 | 22.23 | 22.56 | 24.37 | 23.81 |
Cash Profit Margin (%) | 19.64 | 12.01 | 17.33 | 19.58 | 21.53 | 24.04 | 28.46 | 27.12 | 26.79 | 28.49 | 26.49 |
ROA(%) | 14.91 | 5.75 | 11.22 | 10.95 | 10.36 | 11.25 | 12.2 | 13 | 17.24 | 16.09 | 13.65 |
ROE(%) | 18.77 | 7.63 | 14.75 | 14.7 | 14.11 | 15.07 | 15.89 | 17.19 | 23.3 | 20.55 | 16.21 |
ROCE(%) | 28.96 | 18.19 | 22.78 | 22.62 | 21.49 | 23.22 | 20.38 | 23.62 | 29.78 | 27.56 | 22.37 |
Receivable days | 49.42 | 31.59 | 26.35 | 22.58 | 24.43 | 28.62 | 29.15 | 22.89 | 16.89 | 20.98 | 26.74 |
Inventory Days | 49.61 | 51.1 | 65.25 | 61.01 | 57.05 | 59.95 | 69.32 | 70.57 | 59.41 | 61.77 | 67.09 |
Payable days | 185.5 | 138.79 | 175.52 | 186.15 | 238.01 | 250.57 | 212.28 | 176.59 | 114.15 | 109.36 | 95.85 |
PER(x) | 17.08 | 101.69 | 26.8 | 25.71 | 27.77 | 35.41 | 36.17 | 41.57 | 32.5 | 25.4 | 34.8 |
Price/Book(x) | 5.73 | 5.17 | 3.78 | 3.58 | 3.73 | 5.04 | 5.42 | 8.64 | 6.95 | 4.94 | 5.34 |
Dividend Yield(%) | 28.48 | 0.56 | 0.84 | 1.06 | 0.92 | 0.68 | 8.2 | 0.77 | 0.69 | 2.02 | 0.83 |
EV/Net Sales(x) | 3.12 | 5.18 | 3.55 | 3.63 | 4.18 | 6.38 | 7.53 | 8.74 | 7 | 5.77 | 7.82 |
EV/Core EBITDA(x) | 9.94 | 21.28 | 13.76 | 15.82 | 13.38 | 18.12 | 21.4 | 24.67 | 20.33 | 15.37 | 21.01 |
Net Sales Growth(%) | 6 | 66.69 | 8.58 | -2.29 | 0.11 | 5.74 | 3.37 | 4.04 | 16.64 | -7.13 | -9.55 |
EBIT Growth(%) | -51.02 | -29.69 | 96.98 | 9.96 | 5.76 | 20.59 | -1.23 | 4.68 | 14.54 | 6.88 | -9.07 |
PAT Growth(%) | -56.11 | -54.57 | 203.95 | 10.43 | 6.92 | 19.16 | 18.66 | -2.26 | 23.1 | 1.86 | -11.64 |
EPS Growth(%) | -56.11 | -70.36 | 203.95 | 10.42 | 6.92 | 19.16 | 18.66 | -2.26 | 23.1 | 1.86 | -11.64 |
Debt/Equity(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Ratio(x) | 2.26 | 2.06 | 2.45 | 2.61 | 2.52 | 3.03 | 3.45 | 2.42 | 2.77 | 3.79 | 5.01 |
Quick Ratio(x) | 1.76 | 1.42 | 1.9 | 2.19 | 2.21 | 2.6 | 2.96 | 1.87 | 2.24 | 3.16 | 4.22 |
Interest Cover(x) | 310.56 | 158.68 | 337.93 | 264.69 | 712.57 | 384.67 | 59.36 | 44.45 | 73.23 | 62.13 | 49.35 |
Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
# | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 63.92 | 63.92 | 63.92 | 63.92 | 63.92 | 63.92 | 63.92 | 63.92 | 63.92 | 63.92 |
FII | 2.55 | 2.55 | 2.77 | 2.8 | 2.81 | 2.82 | 3.03 | 3.32 | 3.22 | 3.54 |
DII | 14.83 | 14.88 | 14.93 | 14.9 | 14.89 | 15.01 | 15.15 | 15.33 | 15.84 | 16.03 |
Public | 18.7 | 18.65 | 18.38 | 18.38 | 18.38 | 18.25 | 17.9 | 17.42 | 17.02 | 16.5 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
# | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Promoter | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 | 2.92 |
FII | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.14 | 0.15 | 0.15 | 0.16 |
DII | 0.68 | 0.68 | 0.68 | 0.68 | 0.68 | 0.69 | 0.69 | 0.7 | 0.72 | 0.73 |
Public | 0.86 | 0.85 | 0.84 | 0.84 | 0.84 | 0.83 | 0.82 | 0.8 | 0.78 | 0.76 |
Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
---|
You May Also Know About